SCHEMBL3301915

SCHEMBL3301915

COc1ccc(-c2[nH]nnc2-c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)C(N)CCC(N)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
MAPT P10636 3/20 0.36
GAA P10253 1/20 0.36
CIT O14578 1/20 0.35
LMNA P02545 1/20 0.35
RXFP1 Q9HBX9 1/20 0.34
KDM4E B2RXH2 2/20 0.34
TUBB4A P04350 2/20 0.34
TUBB P07437 2/20 0.34
TUBA3C P0DPH7 2/20 0.34
TUBA1B P68363 2/20 0.34
TUBA4A P68366 2/20 0.34
TUBB4B P68371 2/20 0.34
TUBB3 Q13509 2/20 0.34
TUBB2A Q13885 2/20 0.34
TUBB8 Q3ZCM7 2/20 0.34
TUBA3E Q6PEY2 2/20 0.34
TUBA1A Q71U36 2/20 0.34
TUBA1C Q9BQE3 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL411341 0.99 MEN1 (0.36) MEN1KMT2AMAPTGAACIT
SCHEMBL3304907 0.93 CIT (0.35) MEN1KMT2AMAPTGAACIT
Hydrochloric Acid SCHEMBL412343 0.92 ADAMTS4 (0.35) MEN1KMT2AMAPTGAACIT
SCHEMBL3299214 0.92 CIT (0.39) MEN1KMT2AMAPTGAACIT
Hydrochloric Acid SCHEMBL408290 0.91 CIT (0.38) MEN1KMT2AMAPTGAACIT
SCHEMBL10189798 0.89 FYN (0.37) MEN1KMT2AMAPTGAACIT
SCHEMBL3303340 0.89 MAPT (0.39) MEN1KMT2AMAPTGAACIT
SCHEMBL3300039 0.89 MARS1 (0.38) MEN1KMT2AMAPTGAACIT
SCHEMBL3303169 0.89 SUV39H2 (0.38) MEN1KMT2AMAPTGAACIT
Hydrochloric Acid SCHEMBL412941 0.88 MAPT (0.38) MEN1KMT2AMAPTGAACIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-20100279410-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2010-11-04 US disclosed
US-20100279410-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2010-11-04 US disclosed
US-7781462-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2010-08-24 US disclosed
US-7781462-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2010-08-24 US disclosed
US-20100093670-A1 Compounds for the treatment of angiogenesis SYNTA PHARMACEUTICALS CORP. 2010-04-15 US disclosed
US-20070238699-A1 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. 2007-10-11 US disclosed
US-20070238699-A1 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238699-A1 Compounds for the treatment of proliferative disorders RB1, MKI67, MAPRE1 MEN1 1571/4885KMT2A 2808/4885MAPT 95/4885
US-20100093670-A1 Compounds for the treatment of angiogenesis FLT4, FLT1, TEK MEN1 4135/4885KMT2A 3944/4885MAPT 4120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.